692 related articles for article (PubMed ID: 28688613)
1. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
2. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.
King MT; Yang DD; Muralidhar V; Mahal B; Butler S; Devlin PM; Lee LJ; Mouw KW; Martin NM; D'Amico AV; Nguyen PL; Orio PF
Brachytherapy; 2019; 18(2):186-191. PubMed ID: 30638912
[TBL] [Abstract][Full Text] [Related]
4. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
5. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
6. Brachytherapy boost for prostate cancer: Trends in care and survival outcomes.
Glaser SM; Dohopolski MJ; Balasubramani GK; Benoit RM; Smith RP; Beriwal S
Brachytherapy; 2017; 16(2):330-341. PubMed ID: 28159553
[TBL] [Abstract][Full Text] [Related]
7. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.
Fischer-Valuck BW; Rao YJ; Brenneman RJ; Patel PR; Filson CP; Jani AB; Liu Y; Goyal S; Xu K; Weiss A; Kucuk O; Cimmino C; Szabo S; Rossi P; Baumann BC; Pattaras J; Hershatter B; Patel SA
Brachytherapy; 2020; 19(5):557-566. PubMed ID: 32624405
[TBL] [Abstract][Full Text] [Related]
8. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base.
Amini A; Jones BL; Jackson MW; Rusthoven CG; Maroni P; Kavanagh BD; Raben D
Brachytherapy; 2016; 15(2):136-46. PubMed ID: 26825856
[TBL] [Abstract][Full Text] [Related]
10. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials.
Peinemann F; Grouven U; Bartel C; Sauerland S; Borchers H; Pinkawa M; Heidenreich A; Lange S
Eur Urol; 2011 Nov; 60(5):881-93. PubMed ID: 21763066
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
[TBL] [Abstract][Full Text] [Related]
12. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
Loblaw A; Pickles T; Crook J; Martin AG; Vigneault E; Souhami L; Cury F; Morris J; Catton C; Lukka H; Cheung P; Sethukavalan P; Warner A; Yang Y; Rodrigues G;
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):161-170. PubMed ID: 27780694
[TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes of Dose-Escalated External Beam Radiotherapy versus Combined Brachytherapy for Intermediate and High Risk Prostate Cancer Using the National Cancer Data Base.
Amini A; Jones B; Jackson MW; Yeh N; Waxweiler TV; Maroni P; Kavanagh BD; Raben D
J Urol; 2016 May; 195(5):1453-1458. PubMed ID: 26576709
[TBL] [Abstract][Full Text] [Related]
15. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
16. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
17. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
[TBL] [Abstract][Full Text] [Related]
18. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
19. Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
Pasalic D; Barocas DA; Huang LC; Zhao Z; Koyama T; Tang C; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup AM; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Hoffman KE
Cancer; 2021 Jun; 127(11):1912-1925. PubMed ID: 33595853
[TBL] [Abstract][Full Text] [Related]
20. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
